Newsroom
In the News!
“Virginia mother reunited with newborn after going into COVID-induced coma”
Read More >
Press Releases
FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial
April 21, 2022
FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial AUSTIN, Texas, April 21, 2022 Direct Biologics, a regenerative biotechnology company with a…
Read more
FDA Grants Direct Biologics Regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS
April 12, 2022
FDA Grants Direct Biologics Regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS AUSTIN, Texas, April 12, 2022 Direct Biologics, an innovative biotechnology company…
Read more
Direct Biologics Reveals Successful Outcomes from EXIT COVID-19 Phase II Clinical Trial
April 6, 2022
Direct Biologics Reveals Successful Outcomes from EXIT COVID-19 Phase II Clinical Trial AUSTIN, Texas, April 6, 2022 Direct Biologics, a regenerative biotechnology company with a lifesaving mesenchymal stem cell (MSC)…
Read more
Direct Biologics, LLC Announces One Year Follow Up of Pilot Safety Study of ExoFlo for Treatment of Osteoarthritis in Combat-Related Injuries
November 11, 2021
Direct Biologics, LLC Announces One Year Follow Up of Pilot Safety Study of ExoFlo for Treatment of Osteoarthritis in Combat-Related Injuries Thirty-three Navy SEAL veterans were treated with a bone…
Read more
Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome
July 14, 2021
Direct Biologics Granted FDA Approval of Third IND Application for the use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy Extracellular vesicle product ExoFlo clinical trials to address early stage COVID-19.…
Read more
Direct Biologics Granted FDA Approval for Third IND Application to Investigate the use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy
June 29, 2021
Direct Biologics Granted FDA Approval of Third IND Application for the use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy Extracellular vesicle product ExoFlo clinical trials to address early stage COVID-19.…
Read more
Direct Biologics Receives FDA Approval to Proceed with Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome
June 9, 2021
Direct Biologics Receives FDA Approval to Proceed with Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome Extracellular Vesicle Isolate Product ExoFlo Shows Strong Potential to Treat COVID-19,…
Read more
Innovative Product ExoFlo™ From Direct Biologics Fulfills Unmet but Urgent Medical Need in COVID-19 Treatment
January 28, 2021
Innovative Product ExoFlo™ From Direct Biologics Fulfills Unmet but Urgent Medical Need in COVID-19 Treatment Medical professionals report dramatic and consistent success in treating patients gravely ill with COVID-19-associated Acute…
Read more
Direct Biologics Announces New Advanced Tool in Regenerative Medicine with Launch of AmnioWrap™ Placental Allograft
January 12, 2021
Direct Biologics Announces New Advanced Tool in Regenerative Medicine with Launch of AmnioWrap™ Placental Allograft New Allograft Joins Market Leading ExoFlo™ Extracellular Vesicles in Direct Biologics Product Line AUSTIN,…
Read more
Direct Biologics Announces First Patient Treated Under Phase II Expanded Access Protocol Using ExoFlo™ to Treat COVID-19
December 30, 2020
Direct Biologics Announces First Patient Treated Under Phase II Expanded Access Protocol Using ExoFlo™ to Treat COVID-19 The expanded Access Program provides a pathway for patients to gain access to…
Read more